Tigecycline CAS:220620-09-7

Tigecycline is indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia caused by susceptible organisms. It is administered intravenously due to limited oral bioavailability and is typically reserved for infections where other antibiotics have failed or are not suitable. The dosage and duration of tigecycline therapy depend on the type and severity of the infection, as well as individual patient factors such as renal function and susceptibility testing results. It is usually administered as an initial loading dose followed by maintenance doses at regular intervals. Patients should be monitored for adverse effects such as gastrointestinal disturbances, infusion site reactions, and potential hepatic and renal toxicity. Tigecycline may also cause photosensitivity reactions, so precautions against excessive sunlight exposure are advised during treatment. Due to its broad-spectrum activity and potential for inducing antibiotic resistance, tigecycline should be used judiciously and reserved for situations where alternative treatment options are limited. Consultation with an infectious disease specialist or healthcare professional is recommended for guidance on appropriate use and monitoring of therapeutic efficacy and adverse effects to ensure optimal patient outcomes.